A comprehensive review maps how CAR-NK therapy is moving from concept toward clinical testing, while also cataloging translational barriers that have limited outcomes. The piece highlights engineering levers—signaling domain design, trafficking receptor co-expression, and persistence support such as IL-15—along with manufacturing challenges including lower transduction efficiency than CAR-T and short in vivo persistence.